Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers

被引:293
|
作者
Scheuer, L
Kauff, N
Robson, M
Kelly, B
Barakat, R
Satagopan, J
Ellis, N
Hensley, M
Boyd, J
Borgen, P
Norton, L
Offit, K
机构
[1] Mem Sloan Kettering Canc Ctr, Clin Genet Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dev Chemotherapy Serv, Dept Med, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast & Gynecol Serv, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
关键词
D O I
10.1200/JCO.2002.20.5.1260
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose : To prospectively determine the impact of genetic counseling and testing on risk-reduction strategies and cancer incidence in a cohort of individuals at hereditary risk for breast and ovarian cancer. Patients and Methods: Two hundred fifty-one individuals with BRCA mutations were identified at a single comprehensive cancer center from May 1, 1995, through October 31, 2000. Uniform recommendations regarding screening and preventive surgery were provided in the context of genetic counseling. Patients were followed for a mean of 24.8 months (range, 1.6 to 66.0 months) using standardised questionnaires, chart reviews, and contact with primary physicians. Results: Frequency of cancer surveillance by physical examinations and imaging studies increased after genetic counseling and testing. Twenty-one breast, ovarian, primary peritoneal, or fallopian tube cancers were detected after receipt of genetic test results. Among 29 individuals choosing risk-reducing mastectomy after testing, two were found to have occult intraductal breast cancers. Among 90 individuals who underwent risk-reducing salpingo-oophorectomy, one early-stage ovarian neoplasm and one early-stage fallopion tube neoplasm were found. Radiographic or tumor marker-based screening detected six breast cancers, five of which were stage 0/I, one early-stage primary peritoneal cancer, and three stage I or II ovarian cancers. Six additional breast cancers were detected by physical examination between radiographic screening intervals; four of these six tumors were stage I. No stage III or stage IV malignancies were detected after genetic testing. Conclusion: This study provides prospective evidence that genetic counseling and testing increased surveillance and led to risk-reducing operations, which resulted in diagnosis of early-stage tumors in patients with BRCA1 and BRCA2 mutations. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:1260 / 1268
页数:9
相关论文
共 50 条
  • [1] BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations
    Elezaby, Mai
    Lees, Brittany
    Maturen, Katherine E.
    Barroilhet, Lisa
    Wisinski, Kari B.
    Schrager, Sarina
    Wilke, Lee G.
    Sadowski, Elizabeth
    RADIOLOGY, 2019, 291 (03) : 554 - 569
  • [2] Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers
    Gangi, Alexandra
    Cass, Ilana
    Paik, Daniel
    Barmparas, Galinos
    Karlan, Beth
    Dang, Catherine
    Li, Andrew
    Walsh, Christine
    Rimel, Bobbie J.
    Amersi, Farin F.
    JAMA SURGERY, 2014, 149 (12) : 1306 - 1313
  • [3] Breast cancer after ovarian cancer in BRCA mutation carriers
    Nanez, A.
    Powell, C. B.
    Garcia, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 256 - 256
  • [4] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
    Leendert H Zaaijer
    Helena C van Doorn
    Marian J E Mourits
    Marc van Beurden
    Joanne A de Hullu
    Muriel A Adank
    Luc R C W van Lonkhuijzen
    Hans F A Vasen
    Brigitte F M Slangen
    Katja N Gaarenstroom
    Ronald P Zweemer
    Peggy M L H Vencken
    Caroline Seynaeve
    Mieke Kriege
    British Journal of Cancer, 2016, 115 : 1174 - 1178
  • [5] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
    Zaaijer, Leendert H.
    van Doorn, Helena C.
    Mourits, Marian J. E.
    van Beurden, Marc
    de Hullu, Joanne A.
    Adank, Muriel A.
    van Lonkhuijzen, Luc R. C. W.
    Vasen, Hans F. A.
    Slangen, Brigitte F. M.
    Gaarenstroom, Katja N.
    Zweemer, Ronald P.
    Vencken, Peggy M. L. H.
    Seynaeve, Caroline
    Kriege, Mieke
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1174 - 1178
  • [6] Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    Mcgee, Jacob
    Giannakeas, Vasily
    Karlan, Beth
    Lubinski, Jan
    Gronwald, Jacek
    Rosen, Barry
    McLaughlin, John
    Risch, Harvey
    Sun, Ping
    Foulkes, William D.
    Neuhausen, Susan L.
    Kotsopoulos, Joanne
    Narod, Steven A.
    GYNECOLOGIC ONCOLOGY, 2017, 145 (02) : 346 - 351
  • [7] The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers
    Borreani, C.
    Manoukian, S.
    Bianchi, E.
    Brunelli, C.
    Peissel, B.
    Caruso, A.
    Morasso, G.
    Pierotti, M. A.
    CLINICAL GENETICS, 2014, 85 (01) : 7 - 15
  • [8] Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers
    Fong, Abigail
    Cass, Ilana
    John, Catherine
    Gillen, Jessica
    Moore, Kathleen M.
    Gangi, Alexandra
    Walsh, Christine
    Li, Andrew J.
    Rimel, Bobbie J.
    Karlan, Beth Y.
    Amersi, Farin
    AMERICAN SURGEON, 2020, 86 (10) : 1243 - 1247
  • [9] Breast cancer surveillance following ovarian cancer in BRCA mutation carriers
    John, Catherine S.
    Fong, Abigail
    Alban, Rodrigo
    Gillen, Jessica
    Moore, Kathleen M.
    Walsh, Christine S.
    Li, Andrew J.
    Rimel, B. J.
    Amersi, Farin
    Cass, Ilana
    GYNECOLOGIC ONCOLOGY, 2022, 164 (01) : 202 - 207
  • [10] Breast cancer surveillance following ovarian cancer in BRCA mutation carriers
    Cass, I.
    John, C.
    Gillen, J.
    Moore, K. N.
    Walsh, C.
    Li, A. J.
    Rimel, B. J.
    Karlan, B. Y.
    Amersi, F.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 212 - 213